Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Airway Mucus Plugs in Asthma and COPD: Pathobiology, Imaging, and Implications for Clinical Trials.

American journal of respiratory and critical care medicine·2026
Same author

A Brief History of COPD: As Told by Some of Its Senior Scientists and Clinicians.

Journal of clinical medicine·2026
Same author

Astegolimab for COPD With Frequent Exacerbations: Pooled Analysis of the ALIENTO and ARNASA Trials.

American journal of respiratory and critical care medicine·2026
Same author

Lungs and heart in COPD exacerbations: it takes two to tango.

European journal of internal medicine·2026
Same author

ATS BEAR Cage: 10 years of building education to advance research with innovation, competition, and fun.

ATS scholar·2026
Same author

Body Mass Index-related genetic factors and COPD imaging phenotypes.

Annals of the American Thoracic Society·2026

Related Experiment Video

Updated: May 18, 2026

Observational Study Protocol for Repeated Clinical Examination and Critical Care Ultrasonography Within the Simple Intensive Care Studies
10:38

Observational Study Protocol for Repeated Clinical Examination and Critical Care Ultrasonography Within the Simple Intensive Care Studies

Published on: January 16, 2019

The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol.

Jørgen Vestbo1, Julie Anderson, Robert D Brook

  • 1Dept of Respiratory Medicine J, Odense University Hospital and University of Southern Denmark, Odense, Denmark. jvestbo@dadlnet.dk

The European Respiratory Journal
|September 29, 2012
PubMed
Summary

The SUMMIT trial investigates fluticasone furoate/vilanterol for moderate COPD patients with cardiovascular disease (CVD). It assesses the medication

Keywords:
Cardiovascular diseasechronic obstructive pulmonary diseasemortality

Related Experiment Videos

Last Updated: May 18, 2026

Observational Study Protocol for Repeated Clinical Examination and Critical Care Ultrasonography Within the Simple Intensive Care Studies
10:38

Observational Study Protocol for Repeated Clinical Examination and Critical Care Ultrasonography Within the Simple Intensive Care Studies

Published on: January 16, 2019

Area of Science:

  • Respiratory Medicine
  • Cardiology
  • Clinical Trials

Background:

  • Chronic obstructive pulmonary disease (COPD) frequently coexists with cardiovascular disease (CVD).
  • Comorbidities significantly impact COPD patient health status and prognosis.
  • Limited research exists on COPD medication effects in patients with both conditions.

Purpose of the Study:

  • To determine the impact of fluticasone furoate/vilanterol on survival in moderate COPD patients with CVD.
  • To evaluate the effects of individual components (fluticasone furoate, vilanterol) versus placebo.
  • To assess secondary endpoints including lung function and cardiovascular events.

Main Methods:

  • Multicenter, randomized, double-blind, placebo-controlled trial (SUMMIT).
  • 16,000 patients with moderate COPD and CVD history or risk.
  • Daily treatment with fluticasone furoate/vilanterol, fluticasone furoate, vilanterol, or placebo.

Main Results:

  • Mortality is the primary endpoint, with event-driven powering for fluticasone furoate/vilanterol vs. placebo.
  • Secondary endpoints include FEV1 decline and a composite cardiovascular endpoint.
  • Study design focuses on comparing combination therapy against individual components and placebo.

Conclusions:

  • The SUMMIT study is designed to provide crucial data on the cardiovascular safety and survival benefits of fluticasone furoate/vilanterol in COPD patients.
  • Findings will inform treatment strategies for this high-risk population.
  • The trial addresses a significant unmet need in managing comorbid COPD and CVD.